DE69620727D1 - Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie - Google Patents

Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie

Info

Publication number
DE69620727D1
DE69620727D1 DE69620727T DE69620727T DE69620727D1 DE 69620727 D1 DE69620727 D1 DE 69620727D1 DE 69620727 T DE69620727 T DE 69620727T DE 69620727 T DE69620727 T DE 69620727T DE 69620727 D1 DE69620727 D1 DE 69620727D1
Authority
DE
Germany
Prior art keywords
paclitaxel
beta
prodrugs
prodrug
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620727T
Other languages
English (en)
Other versions
DE69620727T2 (de
Inventor
Bont Hendricus Barthelomeas De
Hidde Jacob Haisma
Ruben Geradus George Leenders
Vos Dick De
Johan Wilhelm Scheeren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmachemie BV
Original Assignee
Pharmachemie BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmachemie BV filed Critical Pharmachemie BV
Application granted granted Critical
Publication of DE69620727D1 publication Critical patent/DE69620727D1/de
Publication of DE69620727T2 publication Critical patent/DE69620727T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C263/00—Preparation of derivatives of isocyanic acid
    • C07C263/12—Preparation of derivatives of isocyanic acid from or via nitrogen analogues of carboxylic acids, e.g. from hydroxamic acids, involving a Hofmann, Curtius or Lossen-type rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69620727T 1995-12-29 1996-12-17 Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie Expired - Fee Related DE69620727T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95203671 1995-12-29

Publications (2)

Publication Number Publication Date
DE69620727D1 true DE69620727D1 (de) 2002-05-23
DE69620727T2 DE69620727T2 (de) 2002-08-22

Family

ID=8221031

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620727T Expired - Fee Related DE69620727T2 (de) 1995-12-29 1996-12-17 Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie

Country Status (10)

Country Link
US (1) US5760072A (de)
EP (1) EP0781778B1 (de)
JP (1) JPH09202796A (de)
AT (1) ATE216394T1 (de)
CA (1) CA2192424C (de)
DE (1) DE69620727T2 (de)
DK (1) DK0781778T3 (de)
ES (1) ES2175028T3 (de)
PT (1) PT781778E (de)
SI (1) SI0781778T1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895784B1 (de) * 1996-04-15 2005-11-23 Asahi Kasei Kabushiki Kaisha Arzneimittelkomplexe enthaltend taxan-verbindungen oder steroiden
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
WO1999018113A1 (fr) * 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
JP2004501143A (ja) 2000-06-22 2004-01-15 ニトロメド　インコーポレーテッド ニトロソ化およびニトロシル化タキサン、組成物および使用方法
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
IL154183A0 (en) * 2001-05-31 2003-07-31 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
CA2478093A1 (en) 2002-02-28 2003-09-12 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
US20050107310A1 (en) * 2002-03-19 2005-05-19 Holick Michael F. Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
EP1549323A2 (de) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Konjugate mit einem wirkstoff für das zentrale nervensystem
US20050203061A1 (en) * 2002-06-20 2005-09-15 Shinya Yamashita Prodrug, medicinal utilization thereof and process for producing the same
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
US20080312162A1 (en) * 2004-10-08 2008-12-18 The Ohio State University Methods and Compositions for Enzyme-Specific Activation of Carbohydrate-Conjugated Prodrugs
FR2947455B1 (fr) 2009-07-01 2014-01-03 Centre Nat Rech Scient La dermaseptine b2 comme inhibiteur de la croissance tumorale
CN110227164B (zh) 2018-03-06 2021-11-23 江苏吉贝尔药业股份有限公司 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
EP4175966A1 (de) * 2020-07-06 2023-05-10 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Polymere mizellen mit glucuronid-prodrugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol

Also Published As

Publication number Publication date
EP0781778A1 (de) 1997-07-02
PT781778E (pt) 2002-08-30
DE69620727T2 (de) 2002-08-22
US5760072A (en) 1998-06-02
ATE216394T1 (de) 2002-05-15
SI0781778T1 (en) 2002-10-31
EP0781778B1 (de) 2002-04-17
CA2192424A1 (en) 1997-06-30
JPH09202796A (ja) 1997-08-05
CA2192424C (en) 2002-01-22
DK0781778T3 (da) 2002-06-17
ES2175028T3 (es) 2002-11-16

Similar Documents

Publication Publication Date Title
DE69620727T2 (de) Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie
AU735243B2 (en) Peptidyl prodrugs and methods of making and using the same
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
CA2336815A1 (en) Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
NZ505339A (en) Camptothecin tetracyclic derivatives useful for inhibiting topoisomerase I and/or II pyridine intermediates thereof
ATE339225T1 (de) Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
CA2211118A1 (en) Stable lipid-comprising drug delivery complexes and methods for their production
AU2003221291A1 (en) Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
NO941819L (no) Lysosomale enzymspaltbare antitumorlegemiddelkonjugater
DE69533615D1 (de) Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
NO924915D0 (no) Sakkarinderivater med inhiberende virkning paa protolytiske enzymer
BR9714063A (pt) Composto, processo para a preparação e uso do mesmo, composição farmacêutica, e, processos para preparação da mesma, para executar a imunossupressão e para tratar ou reduzir o risco de uma doença reversìvel, obstrutiva das vias aéreas
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2083377A1 (en) Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna
EP1132383A4 (de) Neuartige agarofuran derivate, ihre herstellung, pharmazeutische zusammensetzungen, die diese enthalten und ihre verwendung als medizin
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
WO2001051489A3 (en) Methods for lowering uric acid levels
HUP0202974A2 (hu) Fémtartalmú ribonukleotid-polipeptidek

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee